Antibody Information

General Information of This Antibody

Antibody ID	ANI0WCKSM
Antibody Name	INT016
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	V-set domain-containing T-cell activation inhibitor 1 (VTCN1)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

AZD-8205 [Phase 1/2]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Patients 18 years old with cholangiocarcinoma, breast, ovarian or endometrial cancers and ECOG PS 0-1.
*Related Clinical Trial*
NCT Number	NCT05123482	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2a multi-center, open-label master protocol to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of AZD8205 in participants with advanced or metastatic solid malignancies.

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Objective Response Rate (ORR)	69.00%	Positive VTCN1 expression (VTCN1+++/++)
Method Description	In the study of 26 PDX tumors,single administration of 3.5 mg/kg AZD8205 to determine the ORR,according to modified RECIST criteria,which correlated with homologous recombination repair (HRR) deficiency (HRD) and elevated levels of B7-H4 in HRR-proficient models.
In Vivo Model	Multiple tumor PDX model

References

Ref 1	First in human dose-escalation trial with the c-MET targeting antibody-drug conjugate BYON3521. Cancer Res (2023) 83 (8_Supplement): CT185.
Ref 2	Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29(6):1086-1101.